首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   27098篇
  免费   2512篇
  国内免费   2031篇
耳鼻咽喉   304篇
儿科学   240篇
妇产科学   276篇
基础医学   3010篇
口腔科学   354篇
临床医学   3418篇
内科学   3594篇
皮肤病学   216篇
神经病学   1457篇
特种医学   916篇
外国民族医学   9篇
外科学   3124篇
综合类   5519篇
现状与发展   4篇
预防医学   1763篇
眼科学   734篇
药学   3105篇
  21篇
中国医学   1641篇
肿瘤学   1936篇
  2024年   59篇
  2023年   337篇
  2022年   874篇
  2021年   1170篇
  2020年   919篇
  2019年   787篇
  2018年   797篇
  2017年   768篇
  2016年   747篇
  2015年   1147篇
  2014年   1379篇
  2013年   1401篇
  2012年   2165篇
  2011年   2009篇
  2010年   1486篇
  2009年   1217篇
  2008年   1439篇
  2007年   1528篇
  2006年   1547篇
  2005年   1482篇
  2004年   1171篇
  2003年   1270篇
  2002年   1084篇
  2001年   902篇
  2000年   779篇
  1999年   696篇
  1998年   350篇
  1997年   390篇
  1996年   275篇
  1995年   270篇
  1994年   209篇
  1993年   139篇
  1992年   156篇
  1991年   134篇
  1990年   135篇
  1989年   99篇
  1988年   77篇
  1987年   84篇
  1986年   55篇
  1985年   47篇
  1984年   21篇
  1983年   17篇
  1982年   6篇
  1981年   12篇
  1980年   3篇
  1979年   2篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
995.
Hong M  Wu Q  Hu C  Fang J  You Y  Zhong Z  Zou P  Hu Y  Xia L 《Bone marrow transplantation》2012,47(2):196-202
We conducted a retrospective study to evaluate the outcome of 94 consecutive patients with high-risk hematological malignancies who received allo-PBSCT, following idarubicin (IDA)-intensified BUCY2 (IDA-BUCY2) myeloablative conditioning regimens (n=53) and BUCY2 conditioning regimens (n=41). IDA 15?mg/m(2) once daily was administered by continuous infusion on days -11 to -9, followed by BU, 3.2?mg/kg in divided doses daily, on days -6 to -4, and i.v. injection of CY, 1.8?g/m(2) once daily on days -3 to -2 in the IDA-BUCY2 group. The relapse rate in patients in the IDA-BUCY2 and BUCY2-conditioning regimens group was 18.9 and 39%, respectively (P=0.030). There was no significant difference in terms of TRM. The cumulative probabilities of OS and disease-free survival at 2 years for patients conditioned with the IDA-BUCY2 and BUCY2 regimens were 65.3% vs 46.8% (P=0.038), and 63.5% vs 43.4% (P=0.025), respectively. Multivariate analysis showed that IDA-BUCY2 regimens and limited chronic GVHD were the only two factors resulting in improved survival and reduced relapse rate. This retrospective study suggests that IDA-intensified BUCY2 may be substituted for BUCY2 as conditioning regimen for patients with high-risk hematological malignancies.  相似文献   
996.
Objective Patients with primary aldosteronism (PA) who are suitable for surgery should undergo adrenal computerised tomography (CT) and adrenal venous sampling (AVS). A retrospective study was performed of 100 patients with PA. We determined the optimal AVS lateralisation ratio for unilateral disease and reviewed adrenalectomy outcomes evaluating which characteristics predicted hypertension cure. Methods AVS was performed in 93 patients. Lateralisation criteria were assessed using ROC curve analysis. The outcome of adrenalectomy was reviewed in 39 patients and predictive factors for cure determined using univariate and multivariate analysis. Results Of previously published criteria, ROC curve analysis found a cortisol corrected aldosterone affected to unaffected (Aldo/Cort A:U) cut‐off of 2·0 was the best predictor of adenoma identifying 80·4% of patients. A novel ratio calculated by dividing the affected to unaffected ratio by the unaffected to peripheral ratio [(Aldo/Cort A:U)/(Aldo/Cort U:IVC)] was successful in identifying 87·0% of patients. Cure rate for blood pressure after adrenalectomy was 38·5% with improvement in 59·0%. On univariate analysis, predictors of post‐operative hypertension were increased weight, raised creatinine, left ventricular hypertrophy (LVH) and male sex. On multivariate analysis, male sex and higher pre‐operative systolic blood pressure were predictive. Conclusions Patients with PA should have CT scanning and AVS. Aldo/Cort A:U >2·0 is the most accurate of previously published ratios in predicting unilateral disease. When patients were carefully selected for surgery, 97% had cure or improvement in blood pressure control. Further confirmatory work is required on a novel ratio which was even more predictive in our series.  相似文献   
997.
998.
999.
Parkinson's disease is the second most common neurodegenerative disease, and environmental toxins such as rotenone play an important role in causing degeneration of dopaminergic neurons. Melatonin, a major secretory product of pineal, is recently reported to protect against rotenone-induced cell death in animal models. Yet, the mechanism involved in this protection needs to be elucidated. Here, we report that rotenone treatment (0-100 μM) decreased cell survival of Hela cells in a dose-dependent manner. At concentrations ranging from 0.1 to 100 μM, rotenone induced a dose-dependent increase in the expression of microtubule-associated protein 1 light chain 3 (LC3)-II, a protein associated with the autophagosomal membrane. Knockdown of Bax or Omi using shRNA inhibited 1 μM rotenone-induced autophagy. To determine whether melatonin would protect cells against rotenone-induced cell death and autophagy, we pretreated Hela cells with 250 μM melatonin for 24 hr in the presence of rotenone. Melatonin inhibited Bax expression and the release of the omi/HtrA2 into the cytoplasm induced by 1 μM rotenone. Melatonin 250 μM treatment also suppressed cell death induced by 0.1-100 μM rotenone and protected against the formation of LC3-II in cells exposed to 1 μM rotenone. This work demonstrates a novel role for melatonin as a neuroprotective agent against rotenone.  相似文献   
1000.
基因芯片分析NTD小鼠细胞周期和凋亡相关基因表达的变化   总被引:1,自引:0,他引:1  
目的 筛选神经管缺陷(NTD)发生过程中与正常组织差异表达的细胞周期和细胞凋亡相关基因并作初步功能分析.方法 用含有1 100余个已知基因的中密度芯片比较了胚胎9.5d、10.5 d正常与同期NTD小鼠神经管组织的基因表达差异.结果 通过比较正常E9.5d与E10.5 d获得138个差异表达基因,E9.5 d-NTD获得20个差异,El0.5 d-NTD获得29个差异表达基因,根据基因功能分类包括细胞周期与凋亡相关基因,信号转导基因,转录与翻译调控,能量与代谢基因,热休克基因,基质与骨架蛋白等多种种类.而细胞周期和凋亡相关基因分别占差异基因的25.80%(32/124),45.00%(9/20)及28.57%(8/28).结论 实验证实多类基因参与了NTD的发生、发展过程,细胞周期和凋亡相关基因在神经管异常发育中具有重要作用,对该相关基因群的进一步研究有助于阐释NTD的发病机制.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号